Walvax Biotechnology Co., Ltd. (SHE:300142)
12.97
-0.04 (-0.31%)
Sep 16, 2026, 3:04 PM CST
Walvax Biotechnology Revenue
Walvax Biotechnology had revenue of 390.37M CNY in the quarter ending June 30, 2026, a decrease of -43.58%. This brings the company's revenue in the last twelve months to 2.10B, down -17.47% year-over-year. In the year 2025, Walvax Biotechnology had annual revenue of 2.42B, down -14.29%.
Revenue (ttm)
2.10B
Revenue Growth
-17.47%
P/S Ratio
9.89
Revenue / Employee
1.06M
Employees
1,981
Market Cap
20.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | -403.21M | -14.29% |
| Dec 31, 2024 | 2.82B | -1.29B | -31.41% |
| Dec 31, 2023 | 4.11B | -972.67M | -19.12% |
| Jan 1, 2023 | 5.09B | 1.62B | 46.89% |
| Jan 1, 2022 | 3.46B | 523.81M | 17.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Livzon Pharmaceutical Group | 10.75B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Hubei Jumpcan Pharmaceutical | 5.80B |
| Kangmei Pharmaceutical | 4.97B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 4.72B |
| Betta Pharmaceuticals | 3.85B |
| Shanghai Haoyuan Chemexpress | 3.21B |